Clinical trials have demonstrated its potential to reduce levels of interleukin-6 (IL-6), enhance the activity of the antioxidant enzyme GPx, and alleviate symptoms such as anxiety and depression in patients with PCC [20,185]. The gene discussed is IL6; the disease is depressive symptom measurement.